News & Updates

Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.

There appears to be a dearth of evidence on the management of nonrelaxing pelvic floor dysfunction (PFD), a debilitating condition characterized by tension of the pelvic floor muscles that frequently leads to pelvic pain, according to data presented at ACOG 2022.

Administering mifepristone and misoprostol in the emergency departments (EDs) appears to be effective, increasing the availability of early pregnancy loss medical management services to women during the COVID-19 pandemic in the US, as shown in a study presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.

Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.

Pregnant women with allergic rhinitis before and after childbirth see higher rates of thromboembolic (TE) disease and venous complications, a recent study has found.

In pregnant women who present with first-trimester vaginal bleeding, treatment with progesterone throughout pregnancy does not appear to be beneficial in terms of lowering the risk of miscarriage or premature delivery, according to PREEMPT trial presented at this year’s American College of Obstetricians and Gynecologists (ACOG 2022) meeting.